Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma
Cancer Letters · 2023
DOI: 10.1016/j.canlet.2023.216063 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2023. Verfasst von Zhong-Zhe Lin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Departments of Oncology, National Taiwan University Hospita…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Telomerase, Liver Neoplasms, Oncolytic Virotherapy. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Ministry of Science and Technology, Taiwan.
Abstract (Originalsprache)
The telomerase-specific oncolytic adenovirus Telomelysin and the histone deacetylase inhibitor AR42 have demonstrated anticancer effects in preclinical models of human hepatocellular carcinoma (HCC). However, the clinical development of Telomelysin may be hindered by human antiviral immunity and tumor resistance. Combining oncolytic and epigenetic therapies is a viable approach for treating various cancers. This study investigated the potential synergism of Telomelysin and AR42 and the relevant underlying mechanisms. Telomelysin and AR42 exhibited synergistic antiproliferative effects in human HCC models in vitro and in vivo. Apoptosis induced by Telomelysin was significantly enhanced by AR42 in both PLC5 and Hep3B HCC cells. AR42 treatment unexpectedly attenuated the expression of the coxsackievirus and adenovirus receptor and the mRNA levels of human telomerase reverse transcriptase, which may be positively associated with the cytotoxicity of Telomelysin. Meanwhile, the cellular antiviral interferon response was not altered by AR42 treatment. Further, we found that Telomelysin enhanced Akt phosphorylation in HCC cells. AR42 reduced Telomelysin-induced phospho-Akt activation and enhanced Telomelysin-induced apoptosis. The correlation of Akt phosphorylation with drug-induced apoptosis was validated in HCC cells with upregulated or downregulated Akt signaling. Combination therapy with Telomelysin and AR42 demonstrated synergistic anti-HCC efficacy. Clinical trials investigating this new combination regimen are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Departments of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Department of Internal Medicine, College of Medicin…
- Panorama Research Institute, Sunnyvale, CA, USA.
- Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Departments of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, College of Medicine…
- Department of Surgery, College of Medicine, National Taiwan University, Taipei, Taiwan.
- Departments of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
- Department of Biochemical Science and Technology, National Taiwan University, Taipei, Taiwan.
Förderung
- Ministry of Science and Technology, Taiwan
Zitieren
APA
Lin, Z. Z., Hu, M. C., Hsu, C., Wu, Y. M., Lu, Y. S., Ho, J. A., Yeh, S. H., Chen, P. J., & Cheng, A. L. (2023). Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma. Cancer Letters. https://doi.org/10.1016/j.canlet.2023.216063
Vancouver
Lin ZZ, Hu MC, Hsu C, Wu YM, Lu YS, Ho JA, et al. Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma. Cancer Letters. 2023. doi:10.1016/j.canlet.2023.216063
BibTeX
@article{Lin2023,
author = {Lin, Zhong-Zhe and Hu, Mickey C-T and Hsu, Chiun and Wu, Yao-Ming and Lu, Yen-Shen and Ho, Ja-An Annie and Yeh, Shiou-Hwei and Chen, Pei-Jer and Cheng, Ann-Lii},
title = {Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma},
journal = {Cancer Letters},
year = {2023},
doi = {10.1016/j.canlet.2023.216063}
}
EUVIMED